Discovery of a hapE Mutation That Causes Azole Resistance in Aspergillus fumigatus through Whole Genome Sequencing and Sexual Crossing

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Camps, Simone M T ^a   Dutilh, Bas E ^b   Arendrup, Maiken C ^c   Rijs, Antonius J M M ^a   Snelders, Eveline ^a   Huynen, Martijn A ^b   Verweij, Paul E ^a   Melchers, Willem J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; BINDING SITE; BROTH DILUTION; CONTROLLED STUDY; DNA BINDING; FUNGAL GENE; FUNGUS ISOLATION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC TRAIT; HAPE GENE; HOMOLOGOUS RECOMBINATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PLASMID; PROGENY; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PURIFICATION; SEQUENCE HOMOLOGY; THERMODYNAMICS; UPREGULATION;

ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; CCAAT-BINDING FACTOR; CLONING, MOLECULAR; CROSSES, GENETIC; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; GENOME, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PROTEIN ISOFORMS; SEQUENCE ANALYSIS, DNA;

ASPERGILLUS FUMIGATUS;

EID: 84870590660     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050034     Document Type: Article

References (83)

1. Latge JP, (1999) Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12: 310-350.
2. Denning DW, Riniotis K, Dobrashian R, Sambatakou H, (2003) Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 37 Suppl 3: S265-280.
3. Howard SJ, Pasqualotto AC, Denning DW, (2010) Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect 16: 683-688.
4. Snelders E, Melchers WJ, Verweij PE, (2011) Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol 6: 335-347.
5. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347: 408-415.
6. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, et al. (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46: 327-360.
7. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, et al. (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356: 348-359.
8. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, et al. (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356: 335-347.
9. Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, et al. (2010) Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 65: 2116-2118.
10. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, et al. (2011) Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 55: 4465-4468.
11. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, et al. (2008) Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5: e219.
12. Verweij PE, Howard SJ, Melchers WJ, Denning DW, (2009) Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 12: 141-147.
13. Hodiamont CJ, Dolman KM, Ten BI, Melchers WJ, Verweij PE, et al. (2009) Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol 47: 217-220.
14. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, et al. (2009) Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 15: 1068-1076.
15. van der Linden JW, Jansen RR, Bresters D, Visser CE, Geerlings SE, et al. (2009) Azole-resistant central nervous system aspergillosis. Clin Infect Dis 48: 1111-1113.
16. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, et al. (2011) Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 17: 1846-1854.
17. van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE, (2007) Aspergillosis-and a misleading sensitivity result. Lancet 370: 102.
18. Verweij PE, Mellado E, Melchers WJ, (2007) Multiple-triazole-resistant aspergillosis. N Engl J Med 356: 1481-1483.
19. Warris A, Weemaes CM, Verweij PE, (2002) Multidrug resistance in Aspergillus fumigatus. N Engl J Med 347: 2173-2174.
20. Odds FC, Brown AJ, Gow NA, (2003) Antifungal agents: mechanisms of action. Trends Microbiol 11: 272-279.
21. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL, (2001) Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol 39: 2431-2438.
22. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL, (2003) A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 47: 1120-1124.
23. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, et al. (2006) Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 28: 450-453.
24. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL, (2004) Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 48: 2747-2750.
25. Kuipers S, Bruggemann RJ, de Sevaux RG, Heesakkers JP, Melchers WJ, et al. (2011) Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob Agents Chemother 55: 3564-3566.
26. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers WJ, Verweij PE, et al. (2007) A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 51: 1897-1904.
27. Snelders E, Karawajczyk A, Verhoeven RJ, Venselaar H, Schaftenaar G, et al. (2011) The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: The mechanism of L98H azole resistance. Fungal Genet Biol 48: 1062-1070.
28. Albarrag AM, Anderson MJ, Howard SJ, Robson GD, Warn PA, et al. (2011) Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter. Antimicrob Agents Chemother 55: 5113-5121.
29. Lupetti A, Danesi R, Campa M, Del TM, Kelly S, (2002) Molecular basis of resistance to azole antifungals. Trends Mol Med 8: 76-81.
30. Morio F, Loge C, Besse B, Hennequin C, Le Pape P, (2010) Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 66: 373-384.
31. Chamilos G, Kontoyiannis DP, (2005) Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat 8: 344-358.
32. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, et al. (1997) Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 40: 401-414.
33. Nascimento AM, Goldman GH, Park S, Marras SA, Delmas G, et al. (2003) Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother 47: 1719-1726.
34. Rajendran R, Mowat E, McCulloch E, Lappin DF, Jones B, et al. (2011) Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob Agents Chemother 55: 2092-2097.
35. Slaven JW, Anderson MJ, Sanglard D, Dixon GK, Bille J, et al. (2002) Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet Biol 36: 199-206.
36. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, et al. (2009) Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 22: 291-321.
37. Qiao J, Liu W, Li R, (2008) Antifungal resistance mechanisms of Aspergillus. Nippon Ishinkin Gakkai Zasshi 49: 157-163.
38. da Silva Ferreira ME, Capellaro JL, dos Reis ME, Malavazi I, Perlin D, et al. (2004) In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother 48: 4405-4413.
39. Alcazar-Fuoli L, Mellado E, Garcia-Effron G, Buitrago MJ, Lopez JF, et al. (2006) Aspergillus fumigatus C-5 sterol desaturases Erg3A and Erg3B: role in sterol biosynthesis and antifungal drug susceptibility. Antimicrob Agents Chemother 50: 453-460.
40. Dirr F, Echtenacher B, Heesemann J, Hoffmann P, Ebel F, et al. (2010) AfMkk2 is required for cell wall integrity signaling, adhesion, and full virulence of the human pathogen Aspergillus fumigatus. Int J Med Microbiol 300: 496-502.
41. Langfelder K, Gattung S, Brakhage AA, (2002) A novel method used to delete a new Aspergillus fumigatus ABC transporter-encoding gene. Curr Genet 41: 268-274.
42. Qiao J, Liu W, Li R, Wan Z, (2008) Phenotype analysis of Aspergillus fumigatus containing extra copies of ERG3B gene. Chin J Derm Venereo (Chinese) 22: 19-22.
43. Qiao J, Liu W, Li R, (2010) Truncated Afyap1 attenuates antifungal susceptibility of Aspergillus fumigatus to voriconazole and confers adaptation of the fungus to oxidative stress. Mycopathologia 170: 155-160.
44. Richie DL, Hartl L, Aimanianda V, Winters MS, Fuller KK, et al. (2009) A role for the unfolded protein response (UPR) in virulence and antifungal susceptibility in Aspergillus fumigatus. PLoS Pathog 5: e1000258.
45. Willger SD, Puttikamonkul S, Kim KH, Burritt JB, Grahl N, et al. (2008) A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog 4: e1000200.
46. Arendrup MC, Mavridou E, Mortensen KL, Snelders E, Frimodt-Moller N, et al. (2010) Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 5: e10080.
47. Subcommitte on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) (2008) EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 14: 982-984.
48. Camps SM, van der Linden JW, Li Y, Kuijper EJ, van Dissel JT, et al. (2012) Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 56: 10-16.
49. Snelders E, Huis In 't Veld RA, Rijs AJ, Kema GH, Melchers WJ, et al. (2009) Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 75: 4053-4057.
50. Fedorova ND, Khaldi N, Joardar VS, Maiti R, Amedeo P, et al. (2008) Genomic islands in the pathogenic filamentous fungus Aspergillus fumigatus. PLoS Genet 4: e1000046.
51. Nierman WC, Pain A, Anderson MJ, Wortman JR, Kim HS, et al. (2005) Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature 438: 1151-1156.
52. Li H, Ruan J, Durbin R, (2008) Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 18: 1851-1858.
53. Paoletti M, Rydholm C, Schwier EU, Anderson MJ, Szakacs G, et al. (2005) Evidence for sexuality in the opportunistic fungal pathogen Aspergillus fumigatus. Curr Biol 15: 1242-1248.
54. O'Gorman CM, Fuller HT, Dyer PS, (2009) Discovery of a sexual cycle in the opportunistic fungal pathogen Aspergillus fumigatus. Nature 457: 471-474.
55. da Silva Ferreira ME, Kress MR, Savoldi M, Goldman MH, Hartl A, et al. (2006) The akuB(KU80) mutant deficient for nonhomologous end joining is a powerful tool for analyzing pathogenicity in Aspergillus fumigatus. Eukaryot Cell 5: 207-211.
56. Revankar SG, Kirkpatrick WR, McAtee RK, Fothergill AW, Redding SW, et al. (1998) Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol 36: 153-156.
57. Garcia-Effron G, Mellado E, Gomez-Lopez A, Alcazar-Fuoli L, Cuenca-Estrella M, et al. (2005) Differences in interactions between azole drugs related to modifications in the 14-alpha sterol demethylase gene (cyp51A) of Aspergillus fumigatus. Antimicrob Agents Chemother 49: 2119-2121.
58. Mann PA, Parmegiani RM, Wei SQ, Mendrick CA, Li X, et al. (2003) Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother 47: 577-581.
59. Yamada E, Nishikawa H, Nomura N, Mitsuyama J, (2010) T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena. Antimicrob Agents Chemother 54: 3630-3634.
60. Arthington-Skaggs BA, Warnock DW, Morrison CJ, (2000) Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother 44: 2081-2085.
61. Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, et al. (1998) Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 42: 129-134.
62. Mabey JE, Anderson MJ, Giles PF, Miller CJ, Attwood TK, et al. (2004) CADRE: the Central Aspergillus Data REpository. Nucleic Acids Res 32: D401-405.
63. Mabey Gilsenan J, Cooley J, Bowyer P, (2012) CADRE: the Central Aspergillus Data REpository 2012. Nucleic Acids Res 40: D660-666.
64. da Silva Ferreira ME, Colombo AL, Paulsen I, Ren Q, Wortman J, et al. (2005) The ergosterol biosynthesis pathway, transporter genes, and azole resistance in Aspergillus fumigatus. Med Mycol 43 Suppl 1: S313-S319.
65. Schrettl M, Beckmann N, Varga J, Heinekamp T, Jacobsen ID, et al. (2010) HapX-mediated adaption to iron starvation is crucial for virulence of Aspergillus fumigatus. PLoS Pathog 6: e1001124.
66. Veen M, Lang C, (2005) Interactions of the ergosterol biosynthetic pathway with other lipid pathways. Biochem Soc Trans 33: 1178-1181.
67. Anderson JB, Sirjusingh C, Parsons AB, Boone C, Wickens C, et al. (2003) Mode of selection and experimental evolution of antifungal drug resistance in Saccharomyces cerevisiae. Genetics 163: 1287-1298.
68. Barker KS, Crisp S, Wiederhold N, Lewis RE, Bareither B, et al. (2004) Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J Antimicrob Chemother 54: 376-385.
69. da Silva Ferreira ME, Malavazi I, Savoldi M, Brakhage AA, Goldman MH, et al. (2006) Transcriptome analysis of Aspergillus fumigatus exposed to voriconazole. Curr Genet 50: 32-44.
70. Kato M, (2005) An overview of the CCAAT-box binding factor in filamentous fungi: assembly, nuclear translocation, and transcriptional enhancement. Biosci Biotechnol Biochem 69: 663-672.
71. Tanoue S, Kamei K, Goda H, Tanaka A, Kobayashi T, et al. (2006) The region in a subunit of the Aspergillus CCAAT-binding protein similar to the HAP4p-recruiting domain of Saccharomyces cerevisiae Hap5p is not essential for transcriptional enhancement. Biosci Biotechnol Biochem 70: 782-787.
72. Zemzoumi K, Frontini M, Bellorini M, Mantovani R, (1999) NF-Y histone fold alpha1 helices help impart CCAAT specificity. J Mol Biol 286: 327-337.
73. Hortschansky P, Eisendle M, Al-Abdallah Q, Schmidt AD, Bergmann S, et al. (2007) Interaction of HapX with the CCAAT-binding complex- a novel mechanism of gene regulation by iron. EMBO J 26: 3157-3168.
74. Dunkel N, Blass J, Rogers PD, Morschhauser J, (2008) Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol Microbiol 69: 827-840.
75. Dunkel N, Liu TT, Barker KS, Homayouni R, Morschhauser J, et al. (2008) A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot Cell 7: 1180-1190.
76. Hoot SJ, Smith AR, Brown RP, White TC, (2011) An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrob Agents Chemother 55: 940-942.
77. Mogavero S, Tavanti A, Senesi S, Rogers PD, Morschhauser J, (2011) Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1. Antimicrob Agents Chemother 55: 2061-2066.
78. Schubert S, Barker KS, Znaidi S, Schneider S, Dierolf F, et al. (2011) Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob Agents Chemother 55: 2212-2223.
79. Znaidi S, De Deken X, Weber S, Rigby T, Nantel A, et al. (2007) The zinc cluster transcription factor Tac1p regulates PDR16 expression in Candida albicans. Mol Microbiol 66: 440-452.
80. Dolfini D, Gatta R, Mantovani R, (2012) NF-Y and the transcriptional activation of CCAAT promoters. Crit Rev Biochem Mol Biol 47: 29-49.
81. Blatzer M, Barker BM, Willger SD, Beckmann N, Blosser SJ, et al. (2011) SREBP coordinates iron and ergosterol homeostasis to mediate triazole drug and hypoxia responses in the human fungal pathogen Aspergillus fumigatus. PLoS Genet 7: e1002374.
82. Blosser SJ, Cramer RA, (2012) SREBP-Dependent Triazole Susceptibility in Aspergillus fumigatus Is Mediated through Direct Transcriptional Regulation of erg11A (cyp51A). Antimicrob Agents Chemother 56: 248-257.
83. Denning DW, Park S, Lass-Florl C, Fraczek MG, Kirwan M, et al. (2011) High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 52: 1123-1129.